We also need to look at the costs associated with the management of these adverse CV or renal outcomes in India if they do occur eventually in these high-risk T2DM patients, because this is exactly the expenditure that could be prevented by the use of SGLT-2 inhibitors (with/without DPP-IV inhibitors). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.